What is the NAD+ precursor cluster, and which compounds does it cover?

The NAD+ precursor cluster covers five compounds that share one downstream goal — raising cellular NAD+ — but differ in absorption route, evidence base, dose, side-effect profile, and regulation: NMN (β-nicotinamide mononucleotide), NR (nicotinamide riboside), niacinamide (the amide form of vitamin B3, also called nicotinamide), niacin (the acid form of vitamin B3), and NADH (the reduced cofactor form).

Which NAD+ precursor has the strongest single piece of human evidence?

Niacinamide carries the single most rigorous trial: the ONTRAC phase-three randomised controlled trial published in the New England Journal of Medicine in 2015 (Chen et al., n=386), which reported a 23% relative reduction in non-melanoma skin cancer with 500 mg twice daily for 12 months in a high-risk population. No other NAD+ precursor has reached this evidentiary tier.

Is NMN better than NR?

No head-to-head randomised controlled trial in humans has compared NMN and NR on a clinical endpoint. The two precursors collapse to similar intracellular intermediates and both elevate blood NAD+ at typical doses. Claims of superiority either way are not supportable by the current human evidence.

Why is direct oral NAD+ supplementation considered weakly supported?

The NAD+ dinucleotide is large (molecular weight 663 daltons), highly polar, and chemically unstable in stomach acid. It is largely degraded into smaller fragments (NR, NMN, niacinamide) before absorption, which then re-enter the salvage pathway. As of 2026 there is no large double-blind randomised controlled trial demonstrating that oral intact NAD+ raises blood NAD+ in humans more reliably than its precursors do.

What is the role of NADH compared with the precursors?

NADH is the reduced electron-carrier form and is the molecule that directly donates electrons at mitochondrial Complex I. It is not a precursor — it is the operative cofactor that the precursors are ultimately trying to top up indirectly. Stabilised oral NADH has approximately 25 years of human safety data and modest randomised evidence in chronic fatigue syndrome (Forsyth 1999) and jet-lag cognition (Birkmayer 2002).

Does any NAD+ precursor extend human lifespan?

No. No randomised controlled trial of any NAD+ precursor has used lifespan as an endpoint, and no human study has demonstrated lifespan extension. Mouse lifespan studies exist but do not transfer onto human use. The defensible framing is that NAD+ precursors raise blood NAD+ and produce selected functional improvements in some populations.

Which precursor is most appropriate for healthy older adults?

For older adults the densest human evidence cluster is NMN at 250 mg/day, with three independent randomised trials (Igarashi 2022, Kim 2022, Morita 2024) showing functional improvements in walking speed, grip strength, and sleep. Two independent trials also report that afternoon dosing outperforms morning dosing for sleep and sit-to-stand outcomes in older adults — one of the more reproducible chronobiology findings in the supplement literature.

Why is niacin treated differently from the other precursors in this cluster?

Niacin enters NAD+ via the distinct Preiss-Handler pathway and causes cutaneous flushing in over 80% of users at therapeutic lipid-modifying doses (1 to 3 grams per day). The modern post-statin trials AIM-HIGH (2011 NEJM) and HPS2-THRIVE (2014 NEJM) did not show added cardiovascular benefit on top of statin therapy. Ferrell 2024 in Nature Medicine identified the niacin metabolite 4PY as a promoter of vascular inflammation. Niacin therefore sits in a different risk-benefit category from the other precursors and is not recommended for self-supplementation outside medical supervision.

Is the SLC12A8 NMN transporter mechanism settled science?

No. Grozio et al. 2019 in Nature Metabolism proposed SLC12A8 as a mammalian NMN transporter. Schmidt and Brenner 2020 in the same journal reported they could not reproduce the finding. The mechanism remains contested as of 2026. NMN absorption is more reasonably described as involving multiple proposed routes, including intestinal dephosphorylation to NR, and SLC12A8 should be referenced as a contested hypothesis rather than an established route.

What regulatory status do NAD+ precursors have in the United States, the European Union, and Brazil?

In the United States, niacinamide, niacin, NR (Niagen GRAS), and NADH are legal dietary supplements; NMN status was restored on 29 September 2025 when the FDA withdrew its 2022 IND exclusion determination. In the European Union, niacinamide and niacin are authorised vitamin forms (with EFSA Article 13 claims at recommended daily intake levels), NMN is under Novel Food evaluation (six applications pending), NR has Novel Food status with national variation, and NADH is permitted as a supplement in some member states with no central EFSA authorisation. In Brazil, niacinamide and niacin are listed on ANVISA IN 28/2018; NMN, NR, and NADH require case-by-case evaluation, and NMN specifically is under a full-chain prohibition under ANVISA RE 1139/2022 of 7 April 2022.

Where should I start reading if I want one precursor that has the most consumer-relevant evidence per dollar?

Niacinamide. It carries the ONTRAC NEJM phase-three trial for non-melanoma skin cancer reduction at high-risk populations, has EFSA-authorised general nutrition claims at recommended daily intake levels, has a clean and well-characterised long-term safety record across decades of vitamin B3 research, and is by an order of magnitude the lowest-cost member of the family. The honest caveat is that niacinamide does not carry NMN-style human data for muscle, walking speed, sleep, or aerobic capacity.

NAD+ Precursor Cluster · An Evidence-First Hub

The NAD+ precursor family covers five molecules — NMN, NR, niacinamide, niacin, and NADH — that share one biological goal (raising cellular NAD+) while differing sharply in human evidence base, dose, side-effect profile, and regulatory status across the United States, the European Union, and Brazil. This educational hub maps the comparative evidence honestly: where head-to-head human trials exist (almost none), where each precursor is strongest (niacinamide for skin via the ONTRAC NEJM trial, NMN for older-adult walking speed and amateur aerobic capacity, NR for the broadest RCT count, NADH for chronic fatigue research, niacin for legacy lipid research with modern caveats), and where claims have outrun the data. Educational only — not medical advice and not a substitute for clinical judgement.

Quick Orientation

Five molecules are commonly grouped under the heading "NAD+ boosters". Each works by feeding the cellular NAD+ pool, but the routes, doses, and human evidence differ sharply. This cluster page is the comparative orientation for the dedicated sub-pages: NMN, NAD+ direct (background and limits), NMNH (reduced NMN, emerging research compound), and NADH (the reduced cofactor form). Niacin and niacinamide are vitamin B3 forms with their own long histories in public-health and dermatology research; they are referenced here in the comparative tables and in section 4.

Three statements anchor everything below. First, NAD+ concentrations decline with age across multiple human tissues — roughly 40 to 60 percent from young adulthood to the seventies, observed independently by Harvard, Washington University, and the University of Helsinki research groups, and reviewed across the field. Second, oral NAD+ precursors at clinical doses raise blood NAD+ to approximately twice baseline in multiple randomised controlled trials. Third, blood NAD+ elevation is not the same as a clinical benefit, and the strength of evidence for downstream endpoints varies by precursor and by goal.

Five-Member Comparison Table

The table below summarises the cluster on a common set of dimensions. Each cell is referenced to a sub-page or to a citation in section 7.

Compound	Pathway	Strongest single piece of human evidence	Typical studied dose	Notable caveat
NMN (β-nicotinamide mononucleotide)	Salvage pathway via NRK1/NRK2 and NMNAT	Multi-centre dose-finding RCT (Yi 2022/2023, PMID 36482258, n=80) and chronobiology RCT (Kim 2022, PMID 35215405, afternoon dosing in older adults)	250–1000 mg/day; up to 1250 mg/day for 4 weeks validated for safety (Fukamizu 2022)	Long-term (>6 months) human safety data are sparse. Brazil prohibition (ANVISA RE 1139/2022) blocks all NMN supply.
NR (nicotinamide riboside)	Salvage pathway via NRK1/NRK2	Trammell 2016 PK landmark (PMID 27721479) and Brakedal 2022 NADPARK Parkinson brain-NAD+ (PMID 35235780)	300–1000 mg/day; up to 3000 mg/day short term (NR-SAFE 2023)	A 2020 Dollerup trial in insulin-resistant obese men reported no skeletal-muscle benefit — an honest negative result.
Niacinamide (nicotinamide, vitamin B3 amide)	Direct entry into the salvage pool	ONTRAC NEJM phase-three RCT (Chen 2015, PMID 26488693, n=386, 23% reduction in non-melanoma skin cancer)	500 mg twice daily (skin); 500–1000 mg/day general	High doses may inhibit sirtuins; interaction with carbamazepine is theoretical.
Niacin (nicotinic acid, vitamin B3 acid)	Preiss-Handler pathway	Historical CDP-era HDL data; AIM-HIGH 2011 and HPS2-THRIVE 2014 NEJM negative on statin background; Ferrell 2024 4PY signal	1–3 g/day for lipid effect (prescription range)	Flushing in >80% of users; modern post-statin lipid programmes question the risk-benefit at therapeutic doses.
NADH (reduced cofactor)	Direct mitochondrial Complex I electron donor (not a precursor)	Forsyth 1999 chronic fatigue RCT (PMID 10071523, n=26) and Birkmayer 2002 jet-lag cognition RCT (PMID 12385067)	5–20 mg/day enteric-coated	Sample sizes are small; never independently compared head-to-head with the precursor strategies.

The Underlying Biology — Why the Precursors Differ

NAD+ is a small molecule (nicotinamide adenine dinucleotide, molecular weight 663 daltons) that sits at the centre of cellular energy metabolism, DNA-damage repair signalling, and the activity of the sirtuin family of NAD+-dependent deacetylases. Three classes of cellular consumer draw down the NAD+ pool: sirtuins (acting on histones and metabolic regulators), the PARP family of DNA-repair enzymes, and CD38, an ecto-enzyme whose activity climbs with age and chronic inflammation.

The salvage pathway is the dominant route by which mammalian cells regenerate NAD+. In simplified form, intracellular nicotinamide is phosphoribosylated by NAMPT to NMN, which is then adenylated by the NMNAT isoforms (NMNAT1 in the nucleus, NMNAT2 in the Golgi and cytoplasm, NMNAT3 in mitochondria) to NAD+. NAMPT expression declines with age in several tissues — this is the kinetic step that the salvage-feeding precursors target. NMN and NR both feed directly into this loop, NR via dephosphorylation and rephosphorylation through NRK1/NRK2, NMN via either direct transport or intestinal dephosphorylation to NR followed by re-entry. The SLC12A8 NMN transporter hypothesis (Grozio 2019 Nature Metabolism) remains contested after Schmidt and Brenner's 2020 non-replication, and consumer-facing writing should treat it as a hypothesis rather than an established route.

Niacinamide enters the salvage pool directly. Niacin enters via the Preiss-Handler pathway, which uses a different enzymatic chain (NAPRT, NMNAT, NADS) and is a key reason niacin's metabolic behaviour differs from the others — including the cutaneous flushing response that affects more than 80 percent of users at therapeutic lipid-modifying doses. NADH is structurally not a precursor at all but the reduced electron-carrier form that donates electrons directly at mitochondrial Complex I. Treating "NAD+ precursors" and NADH as one homogeneous group obscures this distinction.

Where Each Precursor Is Strongest — A Goal-by-Goal Walk

This section ties the cluster into the goal-level longevity stack, cognitive support, athletic performance, skin beauty, and heart health pages, and into the lifestyle-level senior 60+, athletic performance lifestyle, and high-stress lifestyle pages.

Skin — Niacinamide (Grade A)

For skin endpoints, niacinamide is the only cluster member with a phase-three randomised controlled trial published in the New England Journal of Medicine. The ONTRAC trial (Chen AC, Martin AJ, Choy B, et al. 2015 NEJM, PMID 26488693, n=386) reported a 23 percent relative reduction in non-melanoma skin cancer at 500 mg twice daily for 12 months in a population at high prior-cancer risk, and an 11 percent reduction in actinic keratosis. Allen 2023 NEJM extended the framework into the post-transplant immunosuppressed population. Bissett 2005 (Dermatologic Surgery) reported improvements in wrinkles, hyperpigmentation, and elasticity with topical-plus-oral niacinamide. NMN, NR, and NADH carry no comparable human skin trial.

For the skin beauty goal and the senior 60+ lifestyle, niacinamide is the cluster member to read first.

Walking speed, grip strength, sleep, sit-to-stand in older adults — NMN (Grade B)

Three independent randomised trials in older Japanese adults underwrite the NMN signal in this domain. Igarashi 2022 (PMID 35927255, n=42 older men, 250 mg/day for 12 weeks) reported improved walking speed (p=0.033) and left-hand grip strength (p=0.019). Kim 2022 (PMID 35215405, n=108, 250 mg/day for 12 weeks, morning vs afternoon arms) reported that the afternoon-dosing arm — but not the morning arm — improved five-times sit-to-stand, sleep quality, and self-reported fatigue. Morita 2024 reproduced the chronobiology pattern (afternoon > morning) in 60 older adults. The afternoon-versus-morning dosing finding is one of the more reproducible timing signals in the supplement literature.

For the longevity stack goal and the senior 60+ lifestyle, NMN is the cluster member with the densest human evidence.

Amateur aerobic capacity — NMN (Grade B)

Liao 2021 (PMID 34238308) in 48 amateur runners reported dose-dependent improvements in aerobic capacity at 300, 600, and 1200 mg/day across six weeks. This is the strongest single trial for an athletic-performance endpoint in the cluster. NR carries a separate cardiopulmonary-exercise signal — Bock 2024 in Nature Communications (PMID 38871717) showed a six-minute walk-test improvement in peripheral artery disease patients — but this is a peripheral vascular-disease cohort, not athletes. NADH has a strong mechanistic case (Complex I electron donor) but no randomised athletic-performance trial.

For the athletic performance goal and the athletic performance lifestyle, NMN is the cluster member to consider first; NADH carries mechanistic adjacency only.

Cognitive support — Mixed; honest framing essential

The NADPARK trial (Brakedal 2022 Cell Metabolism, PMID 35235780) showed that NR raised brain NAD+ in Parkinson's disease patients. Motor improvements were exploratory, not confirmed primary endpoints. Vreones 2024 GeroScience (PMID 37994989, n=20) reported sub-domain cognitive improvements in mild cognitive impairment on NR. Niacinamide improved retinal-layer function in glaucoma patients in a crossover trial (Hui 2020, PMID 32212232). NADH carries Demarin 2004 (PMID 15134388, n=26 Alzheimer's, small positive RCT) and Birkmayer 2002 (PMID 12385067, n=35 jet-lag cognition, positive). The defensible framing across the cluster is "neuroprotective biomarker support" — not "improves memory" or "treats Alzheimer's disease".

For the cognitive support goal, the high-stress lifestyle, and senior populations, this is the weakest evidence sector across the cluster and the one most prone to over-claiming in third-party marketing.

Cardiometabolic — Niacin is a cautionary tale

Niacin at therapeutic lipid-modifying doses (1 to 3 grams per day) was the dominant pre-statin HDL-raising agent — Cochrane review work by Schandelmaier et al. 2017 (PMID 28617537) summarises that era. The modern post-statin trials AIM-HIGH 2011 (NEJM PMID 22085343) and HPS2-THRIVE 2014 (NEJM PMID 25014686) showed no added cardiovascular-event benefit when niacin was layered on top of statin therapy, and HPS2-THRIVE in particular reported increased serious adverse events. Ferrell M et al. 2024 in Nature Medicine (PMID 38383798) identified the niacin metabolite 4PY as a promoter of vascular inflammation correlating with major adverse cardiovascular events, a mechanistic warning at high doses. NMN and NR cardiometabolic data are early — Katayoshi 2023 NMN (PMID 36797393) showed a non-significant trend toward reduced arterial stiffness. No precursor in this cluster has positive cardiovascular hard-endpoint evidence at supplement doses.

For the heart health goal, the honest cluster message is "evidence is currently soft and niacin specifically is a cautionary story" — read alongside the medical guideline above.

Transparent Reverse-Correction Disclosures

This hub aggregates and references the dedicated sub-pages. Three cross-cluster reverse-correction items, surfaced during preparation, are disclosed transparently rather than fixed silently:

R-1 · Pencina 2023 MIB-626 trial PMID confusion. Internal indexing previously collapsed Pencina 2023 (PMID 36740954, J Clin Endocrinol Metab) onto the shared PMID 36482258. Correct PMID 36740954 is used here and on the NMN sub-page.
R-2 · Kim 2022 chronobiology PMID confusion. Internal indexing previously collapsed Kim 2022 (PMID 35215405, Nutrients) onto the same shared PMID 36482258. Correct PMID 35215405 is used here and on the NMN sub-page.
R-3 · SLC12A8 controversy disclosure. The 2019 Grozio NMN-transporter hypothesis was previously presented in internal mechanism fields without disclosing the 2020 Schmidt and Brenner non-replication. This hub presents the controversy explicitly in section 3 and on the NMN sub-page.

The dedicated sub-pages carry additional precursor-specific reverse-correction notes (NMN page §11, NAD+ direct page §5, NMNH page §5, NADH page §12).

Regulatory Snapshot — United States · European Union · Brazil

This educational hub focuses on three regulatory markets in line with the asxan.ai international scope: the United States (FDA), the European Union (EFSA), and Brazil (ANVISA). National regulatory frameworks outside these three are not covered on this hub.

Compound	United States · FDA / DSHEA	European Union · EFSA	Brazil · ANVISA
NMN	Legal dietary supplement following 2025-09-29 FDA withdrawal of the 2022 IND exclusion. NDI framework applies.	Novel Food evaluation pending across six applications (Uthever most advanced, public consultation completed Feb 2025).	Full-chain prohibition under RE 1139/2022 (7 April 2022) — covers commercialisation, distribution, manufacture, import, advertising, and use, including cross-border e-commerce.
NR	Niagen GRAS; long-standing structure-function claims under DSHEA.	Novel Food status; national-level variation among member states.	Case-by-case evaluation; not on the IN 28/2018 positive list.
Niacinamide	GRAS as vitamin B3 amide form; standard vitamin labelling.	Authorised vitamin form; six EFSA Article 13 nutrition claims at recommended daily intake levels (energy metabolism, nervous system, psychological function, skin, mucous membranes, reduction of fatigue).	On the IN 28/2018 positive list for dietary supplements.
Niacin (acid form)	GRAS at vitamin doses; sustained-release lipid-modifying products above 500 mg cross into the prescription category (Niaspan).	Authorised vitamin form; safe upper intake limit of the acid form is 10 mg/day, which is far below the lipid-modifying clinical dose range.	On the IN 28/2018 positive list; doses above 1 gram per day may trigger drug-regulatory oversight.
NADH	Legal dietary supplement under DSHEA (Enada and equivalents marketed since the late 1990s).	National-level acceptance varies (e.g. permitted as a supplement in Austria and Germany); zero EFSA-authorised health claims.	No specific approval pathway; case-by-case evaluation.

Standard prohibited-claim language applies across all three jurisdictions. Disease claims (treats / cures / prevents Alzheimer disease, Parkinson disease, type 2 diabetes, cardiovascular disease, cancer, etc.) and lifespan claims ("extends lifespan", "reverses aging") are not permitted regardless of evidence base.

Safety — Cross-Cluster Summary

Detailed dose tables and contraindications are on each sub-page. The cross-cluster safety summary:

Pregnancy and lactation. No adequate human safety data for NMN, NR, NMNH, or NADH. Avoid the supplement-form precursors. Niacinamide and niacin have standard prenatal-vitamin guidance at recommended daily intake levels; supraphysiological dosing should not be self-initiated.
Children and adolescents. No adequate human safety data for the supplement-form precursors.
Active liver disease. Niacinamide and niacin should be approached cautiously; high-dose niacin is documented to cause hepatotoxicity (especially sustained-release formulations).
PARP inhibitors (oncology). Theoretical interaction across the cluster — NAD+ is the substrate for PARP. Oncology supervision is required.
Statin therapy. Niacin should not be self-added to a statin programme; the AIM-HIGH and HPS2-THRIVE trials showed no added benefit and increased adverse events.
Long-term human safety (beyond six months). Sparse for NMN and NR. Strongest long-term data are for niacinamide (12-month ONTRAC follow-up) and NADH (decades of commercial use under DSHEA).

Dedicated Sub-Pages

NMN · β-Nicotinamide Mononucleotide — Layer A deep evidence sheet · 13 human RCTs, three meta-analyses, SLC12A8 transporter controversy, dose-response data, four-market regulatory framework.
NAD+ Direct Supplementation — Background and Limits — Why direct oral NAD+ is weakly supported, what intravenous NAD+ data actually look like, how the precursor strategies relate.
NMNH · Reduced NMN (Emerging Research Compound) — Tier C emerging signal · 0 human RCTs as of 2026-05-26, all preclinical, transparent Tier C framing, regulatory void across the three markets.
NADH · Reduced Nicotinamide Adenine Dinucleotide — Chronic fatigue (Forsyth 1999), jet-lag cognition (Birkmayer 2002), Alzheimer's pilot (Demarin 2004), and the historical Parkinson programme.

Niacinamide and niacin sub-pages are referenced in this hub via the comparison table and the cardiometabolic and skin sections; dedicated sub-pages for niacinamide and niacin remain on the editorial roadmap.

Read the Evidence (deep dive long-form)

For deep-dive narrative across the NAD⁺-axis evidence base (25-year clinical chronology · NMN vs NR precursor decision · reduced NADH vs NMNH redox-form comparison), see the three dedicated evidence articles forming the NAD⁺-axis cluster:

25 Years of NAD⁺ Clinical Evidence — From Niacin to NMN/NR/NADH — full historical chronology Era 1-4 · niacin / niacinamide / NR / NMN / NADH RCT history with honest nulls + transparent reverse-correction disclosures · 30 PubMed citations.
NMN vs NR Decision Tree — 5-dimension oxidized-precursor decision framework (absorption · RCT pool · NAD⁺ elevation · regulatory · safety) · SLC12A8 controversy framing · 21 PubMed citations.
Reduced NADH vs NMNH — NAD⁺ redox-form comparison (NADH chronology Forsyth 1999 onwards vs NMNH preclinical + Vinten 2026 first human pilot) · 17 PubMed citations.

The three evidence articles form the NAD⁺-axis evidence cluster, with explicit peer cross-links among them. Cross-reading all three alongside this cluster hub builds the holistic NAD⁺-axis evidence picture from precursor chronology → decision framework → redox-form choice.

Where ASXAN's Research Focus Sits

ASXAN's research focus across longevity-relevant ingredient categories includes ingredient-level evidence aggregation across NAD+ precursor and reduced cofactor compounds, with the goal of supporting an internationally accessible, evidence-first educational reference. This NAD+ cluster hub is part of that reference and is editorial in nature; it does not promote any specific product, brand, or investment opportunity.

Educational Disclaimer

This page is educational reference content and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Discuss any supplement use with a qualified healthcare provider, particularly if you are pregnant or breastfeeding, take prescription medication, have a diagnosed condition, or are undergoing oncology, cardiology, or endocrinology treatment. Regulatory status varies by jurisdiction; the three markets in scope here are the United States, the European Union, and Brazil.

← All Ingredients